What does CJC-1295 cost in each channel?
Prices in US dollars at the verification date. Ranges are published list or program prices where a primary source exists; notes say when a figure is a typical market range instead.
| Channel | Price (USD) | Notes |
|---|---|---|
| With insurance | Not published | Not covered. Medicare Part D and commercial pharmacy benefits cover FDA approved drugs for accepted indications; compounded or unapproved peptides are paid in cash. [3] |
| Compounded pharmacy | Not published | No lawful compounded price. CJC-1295 was placed on 503A Category 2 in September 2023, its nomination was later withdrawn, and it is not on the bulks list or a component of an approved drug. Products sold as research chemicals for human use are unapproved drugs and are unverified for identity or purity. [1] [2] [4] |
Why is there no price for CJC-1295?
FDA has found compounding pharmacies offering CJC-1295 anyway. [5] [6]
Clinics and telehealth programs may quote you a cash price for CJC-1295. PeptideAgent lists none, for two reasons. There is no CJC-1295 product to price: none is FDA approved, and a pharmacy has no federal basis to compound it. [1] [2] A quoted price is for a product FDA has not checked for safety, effectiveness, or quality, so it is not the price of a reviewed drug. [7]
If you're going ahead anyway: the checklist on the CJC-1295 page. These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound CJC-1295, with or without a prescription. [2]
- Check the pharmacy's license
- What a legitimate prescription and consult look like
- Why this is safer than a research-use-only product
- Questions to ask the pharmacy, the telehealth company, the prescriber, and anyone offering it
What is the list price of CJC-1295?
There is no list price and no licensed channel. Products sold as CJC-1295 with or without DAC are not approved anywhere, and research chemical products sold for human use are unapproved drugs.
Does insurance cover CJC-1295?
Not covered; there is no approved or lawfully compounded product to cover.
What changes the price?
- Absence of any lawful compounding basis since the 2023 Category 2 placement and later withdrawal
Frequently asked questions
How much does CJC-1295 cost without insurance?
No lawful compounded price. CJC-1295 was placed on 503A Category 2 in September 2023, its nomination was later withdrawn, and it is not on the bulks list or a component of an approved drug. Products sold as research chemicals for human use are unapproved drugs and are unverified for identity or purity. [1] [2] [4]
Does insurance cover CJC-1295?
Not covered; there is no approved or lawfully compounded product to cover. [3]
What is the list price of CJC-1295?
There is no list price and no licensed channel. Products sold as CJC-1295 with or without DAC are not approved anywhere, and research chemical products sold for human use are unapproved drugs.
Related pages
From the blog
- CJC-1295 side effects, alone and with ipamorelin
CJC-1295 side effects in small human trials included injection site reactions, headache, flushing, and a faster heart rate. The ipamorelin blend is untested. Neither peptide is FDA approved.
- Peptide stacks: what each common component has shown alone
No trial has tested a multi-peptide stack for muscle growth or fat loss. Nine common stack components ranked by their own human evidence, legal status, and WADA status. No protocols.
Sources
- [1]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list and withdrawn nominations, content current as of April 22, 2026)FDA
- [2]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA
- [3]Medicare.gov: prescription drug coverage (Part D and outpatient drugs)
- [4]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
- [5]FDA warning letter 594743, April 1, 2020, to a state-licensed 503A compounding pharmacy (FDA warning letters database)FDA, 2020
- [6]FDA briefing document, Pharmacy Compounding Advisory Committee, October 29, 2024 (includes ipamorelin)FDA, 2024
- [7]FDA: Compounding and the FDA, questions and answersFDA